

Seroprevalence of bovine anaplasmosis in the southern US

B.K. Whitlock, DVM, PhD, DACT¹; **J.A. Daniel**, PhD²; **B.S. Harvey**, BS¹; **J.K. Johnson**, DVM³; **J.F. Coetzee**, BVSc, Cert CHP, PhD, DACVCP³

¹College of Veterinary Medicine, The University of Tennessee, Knoxville, TN 37996

²Berry College, Rome, GA 30149

³College of Veterinary Medicine, Iowa State University, Ames, IA 50011

Introduction

Bovine anaplasmosis, caused by *Anaplasma marginale*, is the most prevalent tick-transmitted disease of cattle worldwide and a major obstacle to profitable production in the U.S. The introduction of anaplasmosis into a naïve herd can result in a reduced calf crop and increased cull and mortality rates in infected adult cattle. The cost of anaplasmosis to the US beef industry is estimated to be over \$300 million annually. Control of anaplasmosis in the U.S. is predicated on biosecurity and administration of antimicrobials both of which require knowledge of regional prevalence for implementation to be successful. The last reported prevalence of anaplasmosis in cattle in the southern U.S. ranged from 2% to 24%. However, the test used to determine the prevalence, complement fixation, is no longer considered reliable. Therefore, true prevalence of anaplasmosis in this region is likely much higher than previously reported.

Materials and Methods

To determine the number of cases of anaplasmosis diagnosed in veterinary diagnostic laboratories accredited by the American Association of Veterinary Laboratory Diagnosticians (AAVLD) in the southern U.S. over the past 10 years, serologic and necropsy submission data from 2002 to 2012 pertaining to bovine anaplasmosis was requested from 18 AAVLD laboratories located in 14 southern states.

To estimate the prevalence of bovine anaplasmosis in beef cattle in the southern U.S., blood was collected in 2013 from beef cows consigned to slaughter plants in this region and analyzed for anaplasmosis using a commercial competitive enzyme-linked immunosorbent assay (cELISA; Anaplasma Antibody Test Kit, cELISA; VMRD, Inc., Pullman, WA, USA). Blood was collected

and serum was removed and analyzed for antibody against *A. marginale* by cELISA in accordance with the method described by the OIE and recommended by the manufacturer.

Results

Of the 65,328 samples submitted to the accredited laboratories from 2002 to 2012 in eight southern states 12,281 were seropositive for *A. marginale* [AL (1400/17755: 7.9%), AR (307/1848: 16.6%), KY (388/2903: 13.4%), MS (111/402: 27.6%), NC(1146/10537: 10.9%), SC (24/467: 5.1%), TN (5907/10550: 56.0%), TX (2998/20866:14.4%)]. The overall seroprevalence of the samples submitted from these states to accredited laboratories during this time was 18.8% and ranged from 5.1% to 56.0%.

A total of 977 blood samples were collected from beef cows consigned to slaughter plants originating from 7 southeastern states. Of these 977 samples, 127 were seropositive for *A. marginale* by cELISA [AL (3/24: 12.50%), GA (11/237: 4.64%), KY (25/233: 10.73%), MS (38/117:32.48%), MO (19/54: 35.18%), NC (4/24: 16.67%), TN (26/247: 10.53%), and VA(1/41: 2.44%)]. Therefore, the regional seroprevalence for *A. marginale* in beef cows consigned to slaughter plants in the southeastern U.S. is 13.0% with a range of 2.44% to 35.18%.

Significance

Based upon the seroprevalence of samples submitted to AAVLD accredited diagnostic laboratories for anaplasmosis testing and the seroprevalence of samples from beef cows consigned to slaughter plants in the southern U.S. the true prevalence of anaplasmosis in this region is likely much higher than previously reported.

Comparison of two competitive enzyme-linked immunosorbent assays for *Anaplasma marginale* in cattle

B.K. Whitlock, DVM, PhD, DACT¹; **J.A. Daniel**, PhD²; **J.K. Johnson**, DVM³; **W.R. Stensland**, BS³; **C. Chung**, DVM, MS, PhD⁴; **J.F. Coetzee**, BVSc, Cert CHP, PhD, DACVCP³

¹College of Veterinary Medicine, The University of Tennessee, Knoxville, TN 37996

²Berry College, Rome, GA 30149

³College of Veterinary Medicine, Iowa State University, Ames, IA 50011

⁴VMRD, Inc., Pullman, WA 99136

Introduction

Bovine anaplasmosis, caused by *Anaplasma marginale*, is the most prevalent tick-transmitted disease of cattle worldwide and a major obstacle to profitable production in the U.S. Several serological assays such as complement fixation (CF), card agglutination, and competitive enzyme-linked immunosorbent assay (cELISA) have been used in the detection of anaplasmosis carriers. The CF and card agglutination tests are not considered reliable due to low diagnostic sensitivities (<20% and 67%, respectively). Commercially available major surface protein-5 (MSP-5) epitope-based cELISA is more reliable with high sensitivity (99%) and specificity (89%). Recently, maltose binding protein included as fusion protein in the recombinant MSP-5 used in the commercially available cELISA was identified as the source of some false-positive results. A new cELISA test was developed to improve diagnostic specificity by reducing false positive reactions due to maltose binding protein antibodies and other non-specific antibodies in bovine sera. The objective of this study was to compare results generated using the current and new cELISA tests and real-time RT-PCR to provide veterinarians with up to date information regarding the most appropriate test to use for anaplasmosis diagnosis.

Materials and Methods

Blood was collected from 282 adult beef cows consigned to slaughter plants in the southern U.S. Serum was harvested and then analyzed for anaplasmosis using a commercial competitive enzyme-linked immunosorbent assay (cELISA; Anaplasma Antibody Test Kit, VMRD, Inc., Pullman, WA, USA) and a new cELISA

test (VMRD, Inc., Pullman, WA, USA) in accordance with the method recommended by the manufacturer. A confirmatory RT-PCR assay was performed on each blood sample. An *A. marginale*-specific real-time RT-PCR assay was used on RNA extracted from each of the blood samples to detect and quantify a highly conserved and specific region of 16S ribosomal RNA subunit. Sensitivity, specificity, and positive and negative predictive values for both cELISA tests were calculated based upon real-time RT-PCR assay results being the 'true' positives and negatives.

Results

Of the 282 blood samples collected 28 were positive for *A. marginale* by real-time RT-PCR assay for a prevalence of 9.9%. The calculated sensitivity, specificity, and positive and negative predictive values at a prevalence of 9.9% were 85.7%, 96.1%, 70.6%, and 98.4%, respectively for the current cELISA and 82.1%, 96.8%, 74.2%, and 98.0%, respectively for the new cELISA. The degree of agreement of the new and current cELISA with real-time RT-PCR results were both 0.75.

Significance

At a prevalence of approximately 10% the current and new cELISA for diagnosing *A. marginale* may have similar sensitivity, specificity, positive and negative predictive values and agreement with real-time RT-PCR. These results are in disagreement with previous research that indicated the new cELISA had a greater diagnostic specificity than the current cELISA. These results should be validated at different prevalence rates and with multiple reference assays.